Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC)

Supportive Care in Cancer

Volumn 23, Issue 10, 2015, Pages 2917-2923

  Karthaus, Meinolf ^a   Tibor, Csőszi ^b   Lorusso, Vito ^c   Singh Arora, Rajender ^d   Filippov, Alexander ^d   Rizzi, Giada ^e   Borroni, Maria Elisa ^e   Rossi, Giorgia ^e   Grunberg, Steven M ^f  

^a Klinikum Neuperlach   (Germany)

^b Department of Oncology Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet   (Hungary)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d Sujan Surgical Cancer Hospital ^*  (Russian Federation)

^e HELSINN HEALTHCARE SA   (Switzerland)

^f UNIVERSITY OF VERMONT   (United States)

Author keywords

Chemotherapy induced nausea and vomiting (CINV); Cisplatin; Highly emetogenic chemotherapy (HEC); Palonosetron

Indexed keywords

CISPLATIN; DEXAMETHASONE; PALONOSETRON; ANTIEMETIC AGENT; ISOQUINOLINE DERIVATIVE; QUINUCLIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; ASTHENIA; BLADDER CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEOPLASMS; ORAL DRUG ADMINISTRATION; VOMITING;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANTIEMETICS; CISPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; QUINUCLIDINES; VOMITING;

EID: 84940461158     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2657-1     Document Type: Article

References (28)

1. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7(2):189–195
2. Laszlo J, Lucas VS Jr (1981) Emesis as a critical problem in chemotherapy. N Engl J Med 305(16):948–949. doi:10.1056/NEJM198110153051609
3. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, Group EMGW (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243. doi:10.1093/annonc/mdq194
4. Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D (2013) Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. Support Care Cancer 21(5):1453–1460. doi:10.1007/s00520-012-1691-5
5. Navari RM (2010) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 6(7):1073–1084. doi:10.2217/fon.10.74
6. Rojas C, Slusher BS (2012) Pharmacological mechanisms of 5-HT(3) and tachykinin NK(1) receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 684(1–3):1–7. doi:10.1016/j.ejphar.2012.01.046
7. Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting—two new agents. J Support Oncol 1(2):89–103
8. Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, Cantoreggi S, Sebastiani S, Pietra C, Slusher BS (2010) The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 335(2):362–368. doi:10.1124/jpet.110.166181
9. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107(2):469–478. doi:10.1213/ane.0b013e318172fa74
10. Aogi K, Sakai H, Yoshizawa H, Masuda N, Katakami N, Yanagita Y, Inoue K, Kuranami M, Mizutani M (2012) A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer 20(7):1507–1514. doi:10.1007/s00520-011-1239-0
11. Feinberg B, Gilmore J, Haislip S, Jackson J, Jain G, Balu S, Buchner D (2012) Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. Support Care Cancer 20(3):615–623. doi:10.1007/s00520-011-1140-x
12. Longo F, Mansueto G, Lapadula V, Stumbo L, Del Bene G, Adua D, De Filippis L, Bonizzoni E, Quadrini S (2012) Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int J Clin Pract 66(8):753–757. doi:10.1111/j.1742-1241.2012.02969.x
13. Aapro M, Fabi A, Nole F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21(5):1083–1088. doi:10.1093/annonc/mdp584
14. Brugnatelli S, Gattoni E, Grasso D, Rossetti F, Perrone T, Danova M (2011) Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients. Tumori 97(3):362–366. doi:10.1700/912.10035
15. Celio L, Denaro A, Agustoni F, Bajetta E (2012) Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. J Support Oncol 10(2):65–71. doi:10.1016/j.suponc.2011.06.007
16. Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, Fabi A, Capobianco AM, Isa L, Cavanna L, Bertolini A, Bichisao E, Bajetta E (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 19(8):1217–1225. doi:10.1007/s00520-010-0941-7
17. Hesketh PJ, Sanz-Altamira P (2012) Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting. Support Care Cancer 20(3):653–656. doi:10.1007/s00520-011-1312-8
18. Noor R, Bedikian AY, Mahoney S, Bassett R Jr, Kim K, Papadopoulos N, Hwu WJ, Hwu P, Homsi J (2012) Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer 20(10):2583–2588. doi:10.1007/s00520-011-1359-6
19. Choi BS, Borsaru GP, Ballinari G, Voisin D, Di Renzo N (2013) Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy. Leuk Lymphoma. doi:10.3109/10428194.2013.813498
20. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10):1570–1577. doi:10.1093/annonc/mdg417
21. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98(11):2473–2482. doi:10.1002/cncr.11817
22. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441–1449. doi:10.1093/annonc/mdl137
23. Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11(8):522–527. doi:10.1007/s00520-003-0482-4
24. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115–124. doi:10.1016/S1470-2045(08)70313-9
25. Gonullu G, Demircan S, Demirag MK, Erdem D, Yucel I (2012) Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 20(7):1435–1439. doi:10.1007/s00520-011-1226-5
26. Yavas C, Dogan U, Yavas G, Araz M, Ata OY (2012) Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support Care Cancer 20(10):2343–2347. doi:10.1007/s00520-011-1348-9
27. Tsavaris NB, Tsaroucha-Noutsou E, Karvounis N, Bacoyannis C, Pagou M, Kosmidis P (1995) Comparison of different schedules of ondansetron (GR 38032F) administration during cisplatin-based chemotherapy: a randomized trial. Chemotherapy 41(1):70–76
28. Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F, investigators P (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992. doi:10.1093/annonc/mds021